Trial · NCT02063867

Active Bathing to Eliminate Infection (ABATE Infection) Trial

NCT02063867, Not applicable, Completed, University of California, Irvine; results first posted 2019-07-12

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Active Bathing to Eliminate Infection (ABATE Infection) Trial. Trials, record NCT02063867. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02063867

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Active Bathing to Eliminate Infection (ABATE Infection) Trial
NCT number: NCT02063867
Status: Completed
Phases: Not applicable
Enrollment: 53 participants, actual
Lead sponsor: University of California, Irvine
Conditions: Healthcare Associated Infections, Methicillin Resistant Staphylococcus Aureus, Multi Drug Resistant Organisms
Interventions: Arm 2: Decolonization
First posted: 2014-02-14
Last updated: 2019-07-12
Results first posted: 2019-07-12

Source ClinicalTrials.gov

Registered outcomes9

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	MRSA and VRE Clinical Cultures	21 months	Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) clinical cultures attributable to participating units. Defined as occurring \>2 days into a participating unit stay through 2 days following unit discharge
Secondary	Gram-negative Multi-drug Resistant Organism Clinical Cultures	21 months	Gram-negative (GN) multi-drug resistant organism clinical cultures attributable to participating units. Defined as occurring \>2 days into a participating unit stay through 2 days following unit discharge
Secondary	All-cause Bloodstream Infections	21 months	All-cause bloodstream infections attributable to participating units. Defined as occurring \>2 days into a participating unit stay through 2 days following unit discharge. Includes bacterial and yeast pathogens. Skin commensals require two positive blood cultures.
Other	Urinary Tract Infections	21 months	Urinary tract infections attributable to participating units. Defined as occurring \>2 days into a participating unit stay through 2 days following unit discharge
Other	Blood Culture Contamination	21 months	Blood culture contamination
Other	Clostridium Difficile Infection	21 months	Clostridium difficile Infection attributable to participating units
Other	30-Day Infectious Readmissions	21 months	30-Day Infectious Readmissions among patients in participating units
Other	Emergence of Resistance to Chlorhexidine or Mupirocin	21 months	Emergence of resistance to chlorhexidine (among MRSA and select gram-negative bacteria) or mupirocin (among MRSA) for strains isolated from participating units
Other	Cost Effectiveness	21 months	Cost effectiveness of routine care vs decolonization

Source ClinicalTrials.gov

Outcomes13

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	MRSA and VRE Clinical Cultures	21 months	Unadjusted intention-to-treat analysis. Number of patients in the intervention period provided. Analysis involves comparison of baseline and intervention patients (difference in differences)	Hazard Ratio (Intervention vs Baseline)	NUMBER
SECONDARY	Gram-negative Multi-drug Resistant Organism Clinical Cultures	21 months	Unadjusted intention-to-treat analysis. Number of patients in the intervention period provided. Analysis involves comparison of baseline and intervention patients (difference in differences)	Hazard Ratio (Intervention vs Baseline)	NUMBER
SECONDARY	All-cause Bloodstream Infections	21 months	Unadjusted intention-to-treat analysis. Number of patients in the intervention period provided. Analysis involves comparison of baseline and intervention patients (difference in differences)	Hazard Ratio	NUMBER
OTHER_PRE_SPECIFIED	Urinary Tract Infections	21 months
OTHER_PRE_SPECIFIED	Blood Culture Contamination	21 months
OTHER_PRE_SPECIFIED	Clostridium Difficile Infection	21 months
OTHER_PRE_SPECIFIED	30-Day Infectious Readmissions	21 months
OTHER_PRE_SPECIFIED	Emergence of Resistance to Chlorhexidine or Mupirocin	21 months
OTHER_PRE_SPECIFIED	Cost Effectiveness	21 months
POST_HOC	MRSA and VRE Clinical Cultures Among Patients With Devices	21 months	Unadjusted intention-to-treat analysis of sub-population: patients with medical devices (central venous catheters (including accessed ports), midline catheters, or lumbar drains). Number of patients in the intervention period provided. Analysis involves comparison of baseline and intervention patients (difference in differences)	Hazard Ratio	NUMBER

1 to 10 of 13Source ClinicalTrials.gov

See all 13 outcomes

Results by group14

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
MRSA and VRE Clinical Cultures	Arm 1: Usual Care	0.87	95% Confidence Interval 0.79 to 0.95	Hazard Ratio (Intervention vs Baseline)
MRSA and VRE Clinical Cultures	Arm 2: Decolonization	0.79	95% Confidence Interval 0.73 to 0.87	Hazard Ratio (Intervention vs Baseline)
Gram-negative Multi-drug Resistant Organism Clinical Cultures	Arm 1: Usual Care	0.81	95% Confidence Interval 0.72 to 0.91	Hazard Ratio (Intervention vs Baseline)
Gram-negative Multi-drug Resistant Organism Clinical Cultures	Arm 2: Decolonization	0.91	95% Confidence Interval 0.82 to 1.00	Hazard Ratio (Intervention vs Baseline)
All-cause Bloodstream Infections	Arm 1: Usual Care	0.96	95% Confidence Interval 0.85 to 1.08	Hazard Ratio
All-cause Bloodstream Infections	Arm 2: Decolonization	0.90	95% Confidence Interval 0.80 to 1.01	Hazard Ratio
MRSA and VRE Clinical Cultures Among Patients With Devices	Arm 1: Usual Care	1.17	95% Confidence Interval 1.00 to 1.37	Hazard Ratio
MRSA and VRE Clinical Cultures Among Patients With Devices	Arm 2: Decolonization	0.80	95% Confidence Interval 0.69 to 0.92	Hazard Ratio
MRSA Clinical Cultures Among Patients With Devices	Arm 1: Usual Care	1.17	95% Confidence Interval 0.99 to 1.39	Hazard Ratio
MRSA Clinical Cultures Among Patients With Devices	Arm 2: Decolonization	0.87	95% Confidence Interval 0.74 to 1.02	Hazard Ratio

1 to 10 of 14Source ClinicalTrials.gov

See all 14 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants	Units counted
Overall Study	STARTED	Arm 1: Usual Care	156,889	26
Overall Study	STARTED	Arm 2: Decolonization	183,013	27
Overall Study	COMPLETED	Arm 1: Usual Care	152,598	24
Overall Study	COMPLETED	Arm 2: Decolonization	180,048	24
Overall Study	NOT COMPLETED	Arm 1: Usual Care	4,291	2
Overall Study	NOT COMPLETED	Arm 2: Decolonization	2,965	3

Source ClinicalTrials.gov

Adverse events24

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Diffuse rash	Skin and subcutaneous tissue disorders	Arm 1: Usual Care	0	156,889	0
other	Diffuse rash	Skin and subcutaneous tissue disorders	Arm 2: Decolonization	5	183,013	5
other	Diffuse itching	Skin and subcutaneous tissue disorders	Arm 1: Usual Care	0	156,889	0
other	Diffuse itching	Skin and subcutaneous tissue disorders	Arm 2: Decolonization	1	183,013	1
other	Mild rash on trunk	Skin and subcutaneous tissue disorders	Arm 1: Usual Care	0	156,889	0
other	Mild rash on trunk	Skin and subcutaneous tissue disorders	Arm 2: Decolonization	4	183,013	4
other	Mild rash, location unknown	Skin and subcutaneous tissue disorders	Arm 1: Usual Care	0	156,889	0
other	Mild rash, location unknown	Skin and subcutaneous tissue disorders	Arm 2: Decolonization	1	183,013	1
other	Mild rash on limbs	Skin and subcutaneous tissue disorders	Arm 1: Usual Care	0	156,889	0
other	Mild rash on limbs	Skin and subcutaneous tissue disorders	Arm 2: Decolonization	2	183,013	2

1 to 10 of 24Source ClinicalTrials.gov

See all 24 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Arm 1: Usual Care	0	156,889
Total, all-cause mortality	Arm 2: Decolonization	0	183,013
Total, other adverse events	Arm 1: Usual Care	0	156,889
Total, other adverse events	Arm 2: Decolonization	25	183,013
Total, serious adverse events	Arm 1: Usual Care	0	156,889
Total, serious adverse events	Arm 2: Decolonization	0	183,013

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
26772801	DERIVED	PubMed
30850112	DERIVED	PubMed

Grants2

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years	Source
UH3AI113337	Decreasing Bioburden to Reduce Healthcare-Associated Infections and Readmissions	HUANG, SUSAN S.	UNIVERSITY OF CALIFORNIA-IRVINE	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	2014 to 2017	NIH RePORTER
UH2AT007769	DECREASING BIOBURDEN TO REDUCE HEALTHCARE-ASSOCIATED INFECTIONS AND READMISSIONS	HUANG, SUSAN S.	UNIVERSITY OF CALIFORNIA-IRVINE	NATIONAL CENTER FOR COMPLEMENTARY & INTEGRATIVE HEALTH	2012 to 2013	NIH RePORTER

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Arm 2: Decolonization vs Arm 1: Usual Care: deaths from any cause	Trial comparisons
Arm 2: Decolonization vs Arm 1: Usual Care: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02063867

GET https://conductscience.org/api/trials/v1/NCT02063867/events?page=2

API reference For AI assistants